Announced details
Food, beverage and supplement sectors
Confirmed that no adverse effects were observed even at high doses
The disclosure states that adoption is expanding in global markets
Publisher of the company's research paper
Peer-reviewed international academic journal. Other details: Not disclosed
Expected to contribute to medium- to long-term sales growth. Described as an important driver supporting earnings growth
The company does not address Contract Value / Offering price.
Toxicology Reports Volume 16, June 2026, 102249。DOI: 10.1016/j.toxrep.2026.102249
| Item | Details |
|---|---|
| Names of Products / Services Covered | PharmaGABA® (ファーマギャバ) |
| Counterparty | Toxicology Reports (publication) |
| Counterparty overview | Peer-reviewed international academic journal. Other details: Not disclosed |
| Relationship with the Company | Publisher of the company's research paper |
| Applicable area | Food, beverage and supplement sectors |
| Quantitative Effects | Confirmed that no adverse effects were observed even at high doses |
| Usage history | The disclosure states that adoption is expanding in global markets |
| Impact on Business Performance | Expected to contribute to medium- to long-term sales growth. Described as an important driver supporting earnings growth |
| Source | Toxicology Reports Volume 16, June 2026, 102249。DOI: 10.1016/j.toxrep.2026.102249 |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.A comprehensive safety assessment of repeated PharmaGABA® intake confirmed that no adverse effects were observed even at high doses.